Introduction
The mammalian innate-immune system provides an early and important response, not only to foreign antigens but also to any sign commonly associated with infection that the host encounters in a dangerous situation.
The immune system initially responds to 2 major damage signals: exogenous signals (PAMPs) and self-derived signals (DAMPs, also called "alarmins," danger signals, or "endogenous adjuvants"). DAMPs are normally hidden within the cells and released only under conditions of cellular stress, tissue injury, or cell death [1] . They can be actively secreted by distressed cells or released into the extracellular environment from dying cells or from the damaged ECM [2] . Both PAMPs and DAMPs represent the presence of a pathogen or tissue damage. The immune system responds to these signals through ligation to specific receptors (PRRs) and appropriate signaling pathways, thus promoting innate and adaptive immune system activation.
PAMPs and DAMPs include a highly diverse set of molecules, from bacterial lipids or peptides to endogenous proteins, nucleic acids, and metabolites. Among the most relevant PAMPs are LPS from gram-negative outer-membrane, bacterial flagellin lipopeptides, present in gram-positive bacteria, unmethylated C-and G-rich DNA sequences abundant in most prokaryotic genomes, and viral RNA [3] .
Examples of endogenous proteins and nucleic acids that act as DAMPs include IL-1, IL-33, HMGB1, Ab, chromogranin A, ASC, the S100 class of proteins, mt-DNA, nuclear DNA, ATP, uric acid, and ds-and ssRNA [4, 5] .
DAMPs ORIGIN
DAMPs can be released from both extracellular or intracellular space after injury or cell death. Under normal conditions, DAMPs belonging to ECM are sequestered, but upon tissue injury, they can be rapidly released. Some of these components engage multiple PRRs, jointly initiating the inflammatory response. To ensure the continuation of the inflammatory process, cytokine-activated macrophages, followed by tissue-resident cells, start de novo synthesis of intact and soluble ECM-derived DAMPs. In this group, the best characterized DAMPs, to date, are proteoglycans, which are capable of interacting with distinct receptors, such as TLR2, -4, and -6, CD14, and NLRP3 [6] [7] [8] [9] .
However, most DAMPs are of intracellular origin, being released from different compartments or organelles following tissue stress or cellular demise.
DAMPs, such as HMGB1, ATP, IL-1b, and DNA, are released by distressed cells undergoing autophagy or injury without overt cell death [10] . They are also formed through translocation from the nucleus to the cytosol, such as HMGB1, histones, or DNA. During inflammation, they can be released by a dying cell or released extracellularly through vesicular transport [11] . Mitochondria are the main organelles that release various types of DAMPs. When they are injured, they can secrete various intramitochondrial components into the circulatory system, including mt-DNA, formylated peptides, and ATP [12] , all of which are recognized by PRRs. In fact, after release during necroptosis, mitochondria can also act directly as DAMPs [13] .
PRRs
PRRs represent a large group of receptors, including the TLRs, NLRs, AIM2-like receptors, RLRs, and CLRs. They have multiple ligands to bind to PAMPs and/or DAMPs. Most of the TLRs and CLRs are present on the plasma membrane, where they can detect pathogen presence. However, some of them are located in endocytic vesicles, where they monitor these vesicles for microbes that have been ingested [14] . RLRs are also located intracellularly and are involved in the antiviral response. NLRs are present in the cytoplasm and detect the presence the pathogens in this compartment [15] .
TLRs are type I transmembrane proteins characterized by an extracellular leucine-rich repeat domain involved in ligand binding and microbial sensing. At least 10 TLRs have been described in humans and 13 in mice, sharing a similar structure. TLR protein comprises a highly glycosylated N-terminal ectodomain, responsible for ligand detection, a transmembrane region, and an intracellular TIR signaling domain [16] . TLRs associate with a TIR domain-containing adaptor MyD88 to induce the NF-kB translocation from the cytoplasm into the nucleus, where it regulates target gene expression, including proinflammatory cytokines (IL-1, IL-6, IL-8, and TNF-a), chemokines (MIP-1, MCP-1, eotaxin), cell adhesion molecules, immunoreceptors, acute-phase proteins, transcription factors, and oxidative stress-related enzymes. However, TLR3 is an exception, as it induces the activation of the IRF-3 transcription factor, which is required to produce type I IFN responses during viral infection via its adaptor protein TRIF [17] . TLRs are divided in 2 subgroups, according to their initial activation sites in the cell. One subgroup comprises TLR1, -2, -4, -5, -6, and -11, which are expressed on the plasma membrane and recognize proteins, lipids, and lipoproteins of microbial membrane components. The second group includes TLR3, -7, -8, and -9, which are located in intracellular vesicles and primarily recognize nucleic acids [18] .
The CLRs, which identify complex carbohydrates expressed on the cell surface of multiple pathogens, such as viruses, bacteria, and fungi, activate phagocytosis and regulate the innate-immune system [19] . Their stimulation normally results in the induction of signaling pathways that can synergize with TLR signaling pathways, up-regulating cytokine and chemokine production [20] .
NLR family members regulate the immune response to a wide range of stimuli, as pathogens or dangerous conditions. Its members share a similar structure composed of 3 different proteins: 1) an NLR part with an effector domain at the amino terminus consisting of a pyrin domain, which recognizes danger signals ligands; 2) an adaptor protein, recruiting the effector proteins to the complex; and 3) inflammatory caspases as effectors. Depending on their NLR part, they are divided into several classes. NLRP1 (also called NALP1 or DEFCAP), NLRP3 (also known as Cryopyrin, CIAS1, and NALP3), and NLRP4 (also called CARD12 or IPAF) inflammasomes are the best characterized complexes, and their role in the immune system has been shown in vivo in a several studies. The best studied inflammasome is NLRP3, which is a multiprotein complex formed by NLRP3, caspase 1, and ASC. The recruitment of the molecules to form the inflammasome is regulated by their effector domains. Once the complex is created, it initiates caspase-1 self-cleavage and the formation of the active caspase-1, which proteolytically activates pro-IL-1b and pro-IL-18 [21] . Nonetheless, the NLRP3 inflammasome can only process pro-IL-1b and pro-IL-18, which have already been stored in cells. The expression levels of the respective proforms, however, depend on the activation of TLRs.
DUAL RECOGNITION
PAMPs can be recognized and bound by .1 TLR sensor. For example, flagellin, which is sensed by TLR5, is also recognized by an entirely distinct cytosolic sensor, the neuronal apoptosis inhibitory protein-5/Ipaf inflammasome [22] . Another PAMP, which has a dual recognition, is DNA, apart from being recognized by TLR9 and detected in the cytosol by several distinct sensors, some of which still remain to be identified [23, 24] . RNA is recognized by TLR3 within a vesicle and by RIG-I and melanoma differentiation-associated protein 5 in the cytosol [25] .
Flagellin and DNA can activate the inflammasome but only when they are delivered to the cytosol, not in the extracellular space. Thus, immune system activation and regulation depend on both the presence of PAMPs per se but also the particular intracellular or extracellular localization [26] .
This duality is not exclusive to PAMPs but is also shared by several DAMPs. For example, it is known that HMGB1 associates with TLR2, -4, and -9; RAGE; and CD24.
Almost all classes of DAMPs can bind to TLRs [27] ; however, the precise DAMP-TLR complexes were not yet entirely determined. Some evidence shows that DAMPs use the same binding sites as PAMPs [27] . DAMPs also use different accessory proteins to bind to TLRs [28] . Furthermore, the activation of the same receptors may induce different downstream signaling pathways depending on the respective DAMP.
DAMPs IN AD
DAMPs contribute to neuroinflammation in several neurodegenerative disorders, including AD, which is the most common neurodegenerative disease, affecting ;150 million people worldwide. Its pathologic hallmarks include neurofibrillary tangles composed of microtubule-associated protein t, extracellular Αb, and neuronal loss, which together, cause progressive loss of memory and cognitive functions [29] . Approximately 5-10% of the cases are FAD, occurring in an early-onset, autosomal-dominant manner. In FAD, 3 genes mutations are associated with the pathology: APP and PS1 and PS2 [30] . All of these gene mutations cause changes of the relation of Αb peptides through alteration of proteolytic cleavage. However, most of the cases are of a sporadic nature, and the mechanisms involved are not entirely understood. It has been postulated that rather than changes in the proportion of Αb species, an impairment of Ab may be responsible for the majority of sporadic cases [31] .
The amyloid cascade hypothesis is centered around the abovementioned findings in FAD and sporadic AD [32] [33] [34] and was initially driven by the presence of congophilic Ab-enriched plaques in the brains of AD patients [35] . The generation of Tg mice overexpressing 1 or more of the human-mutated genes (APP, PS1, and/or PS2), also presenting these characteristic brain amyloid deposits [36, 37] , further supported the view that Ab represents a key component of AD pathogenesis. Research since has focused on the analysis of Ab and t, the latter being the main component of neurofibrillary tangles. Increasing evidence now indicates that the amyloidogenic processing of APP and the oligomerization of Ab peptides in the brain precede and aggravate t-associated brain pathology [38, 39] . Following the amyloid cascade hypothesis, pathologic alterations of t occur downstream of Ab deposition. However, it is equally plausible that t and Ab changes occur along parallel pathways in AD, thereby enhancing each other's toxic effects [40] .
Similar to prion disorders, toxic conformations of Ab and/or t are generated in AD. These so-called seeds can induce pathologic conformations of normal peptides that cause spreading of the disease [41] . Mutations in APP, PS1, and PS2 probably accelerate the generation of these seeds, whereas in sporadic AD, decreased clearance of Ab [42] or oxidative stress [43] might precipitate the accumulation of toxic Ab species and thus, contribute to the spreading of this pathology throughout brain regions. Recently, increasing evidence has shown that high proinflammatory mediators, including complement components, eicosanoids, chemokines, and cytokines, can be found in the brain and CSF of mild cognitive impairment and AD patients. This suggests that neurodegeneration is accompanied by an inflammatory process that is likely to interfere with the degenerative and compensatory mechanisms involved. The sustained formation and deposition of Ab aggregates cause chronic activation of the innate-immune system [44] . Yet, there are more factors that may maintain and increase the inflammatory component in AD ( Table 1 ). In fact, there are numerous DAMPs involved directly or indirectly in the activation of immune response in this disease.
PRRs, which can trigger inflammatory signaling pathways, are present in the brain, as in all other tissues or organs. They are located in numerous kinds of cells, including microglia, astrocytes, neurons, and endothelial cells. DAMPs activate TLRs and their coreceptors, creating an oxidative and neuroinflammatory environment in AD via excessive production and release of proinflammatory cytokines, ROS, and NO ( Fig. 1) .
NEUROINFLAMMATION AND MICROGLIA ACTIVATION IN AD
In AD, neuroinflammation is not merely a passive system: it contributes to pathogenesis in equal measure with senile plaques and neurofibrillar tangles [44, 45] . It seems that early Ab deposition, t phosphorylation, and subsequent neurofibrillary tangle formation cannot alone cause AD pathology and clinical symptoms but depend on further factors that functionally connect both pathologic hallways. Neuroinflammatory processes could represent one connecting link between Ab and t [46] . Postmortem brains of AD patients show high levels of inflammatory mediators, such as proinflammatory cytokines and chemokines, e.g., IL-1, IL-6, TNF-a, MIP-1b, complement activation products, and oxygen radicals [47, 48] . Functional studies suggest that these mediators can affect neuronal function before causing overt neurodegeneration [31] . Histopathology shows increased numbers of activated astro-and microglial cells surrounding Ab deposits, and these glial changes are replicated in murine models of AD [49, 50] . Importantly, data from GWAS have recently identified mutations in the gene encoding for TREM, which are associated with a higher risk for the sporadic type of AD. However, TREM signaling is intimately linked to TLRs [51] . TREM-1 is an inflammatory amplifier of the signaling, mediated both by TLR and NLR types of pattern recognition systems [51, 52] , and TREM-2 attenuates the TLR-mediated signaling in macrophages and can activate phagocytosis in microglia [51] . TREM-2 potentiates the microglial clearance of apoptotic neurons without causing any inflammation [53] . Furthermore, TREM-2 expression is up-regulated in microglia associated with amyloid plaques in Tg AD mice [54] . It seems that TREM receptors can regulate the balance between phagocytic and inflammatory responses in microglia [46] and thus, provide a possible treatment target.
Ab
Ab is a transmenbrane protein derived from APP by proteolytic cleavage operated by numerous endoproteases, called secretases. The APP processing occurs along 2 pathways: amyloidogenic and nonamyloidogenic. Along the amyloidogenic path, APP suffers sequential proteolysis by BACE and g-secretases producing Ab. Along the nonamyloidogenic pathway, cleavage occurs within the Ab domain by the a-secretase, preventing the formation of amyloidogenic Ab. APP itself is synthesized within the neuronal cell body and transported in an anterograde fashion along axons to nerve terminals in the brain [55] . However, amyloids are not exclusively generated by neurons; similar amyloid fibers are also generated by microorganisms, which manifest as b-sheetstructured peptides across their surface, known as curli fibers. Curli are a class of highly aggregated, extracellular, functional amyloid fibers expressed by several bacteria, such as Escherichia and Salmonella spp, which are involved in the colonization of inert surfaces and biofilm formation and mediate binding to a variety of host proteins [56, 57] .
Misfolded and aggregated Ab elicits an initial immune response that activates microglia already in the oligomer state [31] but certainly, once fibrils have been formed. Microglia represent the principal innate-inmmune cell of the CNS, which constitutes ;10% of all the cells within the nervous system and as such, constitutes the first line of defense against DAMPs and PAMPs. In fact, microglia express most of the TLRs, whereas only a limited set of these PRRs is also present on astrocytes and neurons [58, 59] .
Microglia can be activated through the surface receptor CD36, which contributes to Ab phagocytosis and induces the formation of a TLR2-TLR6 heterodimer with the subsequent NF-kB pathway activation [60] . Furthermore, it has been demonstrated that CD14, a coreceptor of TLR4, is involved in Ab-induced microglial activation [61] . TLR4 can trigger the Ab-induced activation of murine microglia in human monocytes. Furthermore, the direct interaction between TLR2 and human Ab has been shown to trigger inflammatory microglia activation directly [62, 63] . The TLR-mediated mechanism, however, may not only be involved in detrimental immune responses in AD but also in processes that contribute to clearance of the peptide. Thus, TLR9 activation by CpG (analog of bacterial DNA) elicits an innate-immune response in Tg2576 AD mice that leads to the reduction of parenchymal and vascular Ab burden and behavioral improvements [64] . This result is supported by another study, where TLR9 stimulation by CpG oligodeoxynucleotides in 33Tg-AD not only reduced Ab but also attenuated t pathology. These data suggest that the modulation of microglial function through TLR9 stimulation is associated with an Ab clearance and presumably, reduced t pathology in the respective murine AD model [65] .
Upon TLR activation by Ab aggregates, the NLRP3 inflammasome assembles, and subsequently, IL-1b levels rise in the affected brain regions (Fig. 1) . In human AD, caspase-1 expression is increased compared with nondemented, agematched controls. With the use of knockout mouse models, it has been demonstrated that the deficiency for NLRP3 and caspase-1 protected these animals from Ab pathology, synaptic impairment, and cognitive dysfunction [66, 67] .
Apart from the NLRP3 inflammasome, Ab also activates NLRP1. In the brain, NLRP1 is highly expressed in pyramidal neurons and oligodendrocytes, which also express ASC and caspase-1. The mechanism by which Ab activates the inflammasome may include several mechanisms, including TLR4 binding and potassium efflux [68, 69] . Thus, it has been shown that low potassium concentrations increase ASC dimerization and ASC speck formation and activate caspase-1, which then cleaves pro-IL-1b and pro-IL-18 [70] . Ab oligomers may disturb the function of potassium channels, decrease the intracellular K + concentration (decreasing its intracellular concentration) [71] , and increase the expression and activity of the voltage-gated potassium channel Kv3.4, which physiologically is involved in the control of transmitter-release neuronal excitability [72] .
Together, this suggests that beyond other immune mechanisms leading to NLRP activation, ion channel dysregulation may play a role in the pathogenesis of AD neuroinflammation [73] .
HMGB1
HMGB1, also known as amphoterin, is a 25-30 KDa nuclear, nonhistone, DNA-binding protein expressed in all vertebrate tissues, including neurons and glial cells [74] . This protein is highly conserved during evolution. Its sequence is 99% identical among all mammalian species, with only 2 amino acid residues (out of a total of 215 known ones), differing between rodents and humans. Structurally, HMGB1 is composed of 2 DNA-binding domains-the A box (related with its anti-inflammatory effect) and the B box (involved with DNA binding and proinflammatory activation)-and a negatively charged acidic C-terminal tail responsible for DNA damage repair. It has numerous roles in health and inflammation, acting as a DNA chaperone regulating various chromatin processes, such as DNA transcription and replication [75] . However, when it is released into the [77, 78] . When actively secreted, HMGB1 promotes inflammation; however, passive release results in initiating inflammation [79] . It cooperates with other factors, such as chemokines, growth factors, and cytokines, and in addition, orchestrates the inflammatory and immune response [80] .
HMGB1 contains 2 important binding sites for TLRs and RAGE that potentiate the migration, proliferation, and differentiation of immune cells [81] . Importantly, HMGB1 isoforms of different redox states are involved in activating immune cells [76, 82] . These redox states result from post-translational modifications dependent on 3 cysteine residues at positions 23, 45, and 106. HMGB1 interacts with TLR4 via the disulfide bond at C23 and C45 and the free thiol at C106 [82] and induces cytokine production. In contrast to its inactive form, which contains disulfide bonds at all 3 sites, HMGB1 does not interact with TLR4 but interacts with CXCL12 to promote chemotaxis [32] . CXCL12 is secreted by immune cells after NF-kB activation, and HMGB1 itself can induce CXCL12 production via RAGE engagement [83] . HMGB1 is known to associate with PAMPs, as in the case of LPS, and acts as a coreceptor for TLR9, -4, and -2 [84] . Furthermore, it can form complexes with TLR9, enhancing its sensibility to CpG [85] , and stimulate TLR2 association with nucleosomes from apoptotic cells [86] .
HMGB1 bound to RAGE mediates signals for neuronal outgrowth and promotes activation of TLR9-mediated cytokine production. When HMGB1 binds to RAGE, it triggers the activation of Ras, PI3K, and Rho, which drive NF-kB activation [87] . This NF-kB activation occurs also when HMGB1 binds to TLR9 and TLR4, with CD14 required for activation in the case of TLR4 [88, 89] .
A role of HMGB1 in AD has already been suggested. One of the first studies revealed an interaction of HMGB1 with Ab and the stabilization of Ab42 oligomers [90] . Studies in vivo detected HMGB1 in both the cytosolic and particulate fractions in healthy controls and AD patients. However, HMGB1 levels were significantly higher in AD versus control patients, and immunostaining showed a colocalization of Ab and HMGB1, suggesting that HMGB1 may accumulate in senile plaques [90] . Studies on Ab clearance showed that HMGB1 stimulation reduced Ab phagocytosis by rat microglia by over 60% [90] . Furthermore, coinjection of HMGB1 and Ab42 into the brain compromised Ab42 phagocytosis in the rat hippocampus [91] .
Loss of long-term memory, a clinical symptom in AD, was further aggravated by intracerebroventricular injection of HMGB1. Because this effect was blocked by TLR4 antagonist injection in RAGE-deficient mice, both TLR4 and RAGE receptors seem to be instrumental for HMGB1-induced memory dysfunction [92] .
In Tg2576, an established murine AD model, deletion of p35, a neuronal activator of cyclin-dependent kinase 5, increases mortality and impairs spatial learning and memory at 6 mo of age. This phenotype was accompanied by a reduction of pre-and postsynaptic markers an increased neuronal death in the hippocampus and further elevated HMGB1 secretion. Thus, Ab is able to increase HMGB1 secretion, and this secretion is able to promote neuronal cell death further [93] .
Therefore, Ab stabilization through HMGB1, inhibition of microglial phagocytosis, and HMGB1 release in response to Ab in concert promotes neuronal death and synaptic destruction and consequently, results in behavioral deficits. S100 PROTEINS S100 proteins, also known as calgranulins, are small (10-12 KDa) calcium-binding proteins that are expressed exclusively in vertebrates. Twenty-four members have been identified to date, which are classified into 3 subgroups, depending on their intracellular, extracellular, or ubiquitous function. However, all of them contain 2 EF-hand, calcium-binding domains and share ;50% homology [94, 95] . They are expressed in a wide range of tissues, but each member of the family exhibits a unique expression pattern with several cells expressing multiple members of the S100 protein family. In some cases, a particular S100 protein can be induced by pathologic circumstances in cell types, where it is not expressed physiologically. S100 proteins regulate a wide range of cellular functions: thus, they modulate cell growth and differentiation, structural organization of membranes, cytoskeleton dynamics, protection from oxidative cell damage, and protein phosphorylation and secretion [95, 96] . S100 proteins can be secreted extracellularly and act as DAMPs during pathologic processes, regulating critical functions of the innate-immune system. Among them are S100A8, S100A9, S100A12, and S100B. Regarding neurodegenerative disorders, the best-studied proteins are S100A9 and S100B. S100B is expressed in astrocytes and certain neuronal and dendritic cell populations. It acts as stimulator of cell proliferation and migration and inhibitor of apoptosis and differentiation, which participate in neurodegenerative processes [97] . When released from astrocytes, it executes different functions depending on the local concentration. Whereas low concentrations of S100B possess trophic effects, higher concentrations enhance ERK1/2 and ROS production and potentiate the neurotoxic effects of Ab, mediated by RAGE receptor activation [98] . S100B has been found at Ab plaques in AD brains [99] and also in CSF, where it is an experimental status marker for AD. Thus, patients with high levels of S100B show low cognitive scores and vice versa, suggesting that S100B may be an inverse indicator of cognition status in AD [100] . S100B null mice show enhanced spatial and fear memory phenotypes and LTP in the CA1 region. This deficiency is reverted by perfusion of hippocampal slices with S100B, which restores LTP levels to the range usually observed in hippocampal slides derived from wild-type slices [101] . Moreover, genetic deficiency for S100B results in reduced Ab plaque deposition [102] , and it has also been shown that its pharmacological inhibition with arundic acid leads to plaque reduction in Tg2576 AD mice [103] . Although the precise mechanism by which S100B contributes to AD pathogenesis is not well understood yet, it is known that S100B overexpression accelerates AD-like pathology with enhanced astro-and microgliosis [104] . S100A9 is an inflammation-associated, calcium-binding protein expressed in microglia [105] . It has been shown that S100A9 is increased at Ab plaque deposits and reactive glia, suggesting its participation in the inflammatory process in AD [106] . These findings are replicated by 2 different murine AD models, which show an increased S100A9 expression when compared with wild-type mice [107] . Up-regulated S100A9, in reactive microglia, activates the p38 MAPK cascade NF-kB or calcium-dependent signal transduction [108] . It is involved in the production of proinflammatory cytokines, regulation of neurite extension, cell migration, and calcium homeostasis [109] . This up-regulation was initially evidenced in brains of Tg2576 and CT-Tg mice and also in human AD patients and can be induced by Ab and CT peptides in a concentration-dependent manner. The connection between S100A9 and AD was supported by learning and memory tests performed in these animals, where the respective knockdown animals showed improved cognitive performance. The Ab plaques in these mice showed a significant reduction, paralleled by a decrease of BACE1 activity [107] . Similar behavioral results were obtained in an APP/PS1 mouse model, where the lack of S100A9 resulted in decreased Ab burden [110] . In this model, the Ab reduction was a consequence of an altered APP processing caused by decreased transcription of BACE1 and -2. Furthermore, prevention of excessive microglial activation favored Ab degradation by microglial phagocytosis in these animals [110] .
CHROMOGRANIN
Chromogranins, chromogranin A and B, are relatively abundant, acidic proteins that are localized in secretory vesicles. They are expressed in endocrine cells and peptidergic neurons and are responsible for the regulation of secretory pathways, controlling delivery of peptides, hormones, neurotransmitters, and growth factors [111] . Chromogranin A is a member of the granin family, present in secretory vesicles of endocrine and neuronal cells.
There is some evidence showing that chromogranin peptides are altered in AD brains. Chromogranin A levels were increased within the temporal cortex of AD patients inversely to secretogranin II [112] . Moreover, a high percentage of senile plaques was found to contain chromogranin A-reactive dystrophic neurites [112] .
A high number of chromogranin A containing plaques are surrounded by activated microglia. Chromogranin A activates microglia and stimulates the release of cytotoxins, suggesting that it can contribute to the continued and neurotoxic activation of microglia by increasing NO production, mitochondrial depolarization, and the release of neurotoxins [115, 116] . Chromogranin A also activated cultured microglia, inducing the release of IL-1b, indicating that the TLRs and NLRP3 inflammasome are required for this signaling pathway [117] . Together, these data suggest that chromogranin A, once released by neuronal stress or demise, acts as DAMP in AD. Thus, it may sustain the inflammatory process observed in this neurodegenerative disease.
It has been shown that chromogranin A can bind to RAGE, regulating its neuronal/neuroendocrine phenotype [118] . RAGE binding to accumulating Ab fibrils may up-regulate chromogranin A. In turn, chromogranin A secretion could activate microglial cells, which release neurotoxins that sustain inflammation in the AD brain, as described above [119] .
CIRCULATING DNA
Healthy individuals show low circulating DNA (mt-DNA and cf-DNA) levels, but they are increased in the plasma of patients suffering from various disease [120] . These high levels are linked to systemic inflammatory conditions, oxidative stress, or tissue damage [121] .
When mt-DNA is released extracellularly, it can act as a DAMP, causing inflammation [12] . Mitochondria are organelles that evolved from bacteria and contain unmethylated C-and G-rich DNA sequences. Then, when mt-DNA is released, it can bind to TLR9 and activate immune responses. The binding to TLR9, expressed by immune cells, such as monocytes and granulocytes, induces the release of interferon type 1 and TNF-a through the activation of IL-1R-associated kinase 1, 2, and 4 and the phosphorylation of p38 MAPK [122, 123] .
Increasing evidence suggests that mitochondrial dysfunction occurs early in AD, before overt neurodegeneration. Initially, it was shown that AD brains present more nicking and fragmentation of mt-DNA compared with controls, indicative for an increased mt-DNA release and a possible stimulatory role for the inflammatory process in AD [124, 125] .
Ab peptides can accumulate in the mitochondrial matrix of APP mice and also in the brain of AD patients. This accumulation impairs oxygen consumption and decreases complex III and IV activity [126] . Intramitochondrial Ab interacts with and inhibits amyloid-binding alcohol dehydrogenase. This results in increased ROS levels and impaired energy metabolism, a mechanism likely to contribute to spatial learning/memory deficits observed in murine AD models [127] . High ROS levels, together with a decline in the energetic capacity, induce the mitochondrial permeability transition pore opening and activate the apoptosis-inducing factor and apoptosis that may contribute to neuronal degeneration in AD [128] . Furthermore, oxidative stress has been shown to increase BACE1 expression through an activation of c-Jun amino-terminal kinase and p38 MAPK [129] and furthermore, enhances aberrant t phosphorylation through activation of glycogen synthase kinase 3 [130] .
cf-DNA, in its different forms, ss-and dsDNA and -RNA, released from apoptotic or necrotic cells, acts as a DAMP and can be used as a marker of inflammatory activation or tissue damage. cf-DNA can bind to TLR and non-TLR receptors. When it binds to TLRs, specifically to TLR9, it signals through MyD88, resulting in an IRF-7-mediated type-I IFN response, NF-kB, or MAPKdependent cytokine and chemokine production [131] . cf-DNA can also bind to AIM2, leading to caspase-1 activation and subsequent IL-1b release.
However, nucleic acids that derive from the apoptotic or necrotic cell demise are not the only ones involved in the immune response activation. As mentioned above, 4 TLRs-TLR3, -7, -8, and -9-are responsible for nucleic acid recognition; thus, TLR3 recognizes viral dsRNA, TLR7 and TLR8 bind to viral or bacterial ssRNA, and TLR9 binds to bacterial and viral DNA [18] . Only 2 of the TIR-containing signaling adaptors are used by these receptors-TLR7 and TLR8. The TLR9 signal is mediated by MyD88, and the TLR3 signal acts through TRIF. Nontheless, all of them ultimately lead to cytokine production and initiate the transcription of several genes involved in the immune response. Moreover, the AIM2 can be activated by bacterial and viral components through the recognition of DNA in a sequence-independent manner [23, 24, 131] . However, it currently remains unclear which factors are critical for the induction of type I IFN or inflammasome activation [132] .
With respect to AD, high cf-DNA levels have been reported in brains of AD patients [125] .The high amount of nucleic acids released in the AD brain may result from increased necrotic and apoptotic death, e.g., caused by the described oxidative bursts, excitotoxicity, and inflammatory changes. Therefore, it seems likely that the release of DNA or RNA from previously intact cells of either origin will further fuel the inflammatory activation in the AD brain, thereby establishing a vicious cycle.
HSPs
HSPs are a family of proteins that play an essential role as chaperones. They facilitate the proper folding and assembly of nascent polypeptides and mediate the refolding and stabilization of damaged polypeptides. HSPs have been classified into 6 major families on the basis of their molecular weight, including HSP100, -90, -70, -60, and -40 and small HSPs (e.g., aB crystallin and HSP27) [133] . Different classes of HSPs play a diverse role in influencing proper protein assembly, folding, and translocation. HSP70, -60, and -27 prevent protein aggregation and help protein folding, HSP100 releases proteins from aggregates, and HSP90 acts in the maturation and activation of a number of proteins [134] . HSPs are up-regulated in response to tissue stressors, such as elevated temperature, osmotic shock, and cytotoxic agents [135] .
HSPs can be secreted actively, again via nonclassical pathways, including exosomes, and released passively by necrotic cells. Extracellular HSPs can interact with several receptors, including PRRs, inducing the production of inflammatory cytokines, such as TNF-a, IL-1b, IL-12, and GM-CSF [136] . HSP70, through the stimulation of TLR2 and TLR4 and the activation of MyD88/NFkB pathways, induces this cytokine production [137] . Similar results were obtained by Luong et al. [138] . They found that the ligation of HSP70 with TLR4 leads to increased concentration of TNF-a. It has been observed that cytosolic HSP70 can inhibit the activity of NF-kB and while located in the plasma membrane, may contribute to the activation of NF-kB [139] . Under stress conditions, HSP70 usually accumulates in both cellular compartments. Furthermore, HSP70 can be taken up by APCs, which allow the cross-presentation to the immune system of peptides associated with the HSP70 [140] [141] [142] .
The role of HSPs in neurodegenerative diseases has received considerable attention, in particular, in AD.
In spite of their proinflammatory properties, HSPs also have a neuroprotective role in neurodegenerative disorders. In AD, HSP70 is induced in various neural cells, including reactive astrocytes, oligodendrocytes, and microglia [143] . HSP90, together with HSP70/HSP40, prevents Ab formation and slows the rate of aggregation in a chaperone concentration-dependent manner [144, 145] , and the complex HSP70/HSP40 prevents aggregation of the t protein [146] . There are 2 mechanisms by which HSPs inhibit Ab assembly. In 1 pattern, the chaperone binds misfolded Ab in an ATP-independent manner, preventing it from aggregation, and on the other hand, the chaperone may bind Ab in an ATP-dependent manner, changing Ab conformation to one that is less susceptible to aggregation [144, 147] . HSPs also increase the competence of microglia to take up monomeric and aggregated Ab1-42 peptides and then degrade these peptides [148] . These findings indicate that HSPs help to restore the balance between an intracellular peptide or protein aggregation and degradation, thus protecting cells from the cytotoxic effects of such aggregation. HSP70 also plays a cytoprotective role in AD by suppression of Ab aggregation [145, 149] , enhancing the clearance of Ab, restoring t homeostasis, and inhibiting neuronal apoptosis [150] . HSP60 also plays a protective role in the mitochondrial matrix, where it and its partner HSP10 are among the dominant stress proteins, preventing aggregation of Ab [151] , which would exert toxic effects, primarily by inhibiting oxidative phosphorylation [143] .
THERAPEUTIC TARGETS
Until recently, most studies have focused on modulating the pathologic role of Ab and t in AD and related models. Data coming from GWAS now indicate that inflammatory mechanisms are profoundly implicated in disease initiation and progression. Given the increasing role of endogenous danger signals for initiating and sustaining the cerebral immune response during neurodegeneration, one may hypothesize that DAMPs, along with their receptors, potentially represent new therapeutic targets for AD.
Nevertheless, as most of the described DAMPs have a double role, playing important roles for several physiologic cellular process, any modulation or blockade of their action needs to be evaluated and considered carefully. The targeting of the involved molecules with specific inhibitors, which exclusively target extracellular DAMPs, seems to be 1 challenge out there. One possible option may be to disrupt specific residues or domains involved in the interaction of DAMPs and PRRs [27] .
Future research will test whether modulation of DAMP or PRR expression can be used for AD treatment. Recently, Gilchrist and colleagues [152] identified ATF3, a member of the CREB/ATF family of transcription factors, as a potent suppressor of TLRmediated gene expression, offering another new target to control the immune system activation. Another intervention may target the assembly of the NLRP3 inflammasome, resulting in reduced inflammation [153] .
As IL-1b may be one of the most important inflammatory cytokines in AD and also acts as a DAMP, 1 option could be the blockade of its receptor through anakinra, a recombinant IL-1R antagonist. In Tg2576 mice, the intrahippocampal transplantation of neural precursor cells with this antagonist improved impairments of memory and neurogenesis [154] . In keeping with this, anakinra prevented the production of high levels of proinflammatory cytokines in APP/PS1 mice [155] .
CONCLUSIONS
Inflammation plays an important role in AD. In fact, the innateimmune system may primarily act as a defense mechanism, misinterpreting the misfolded and aggregated Ab species as bacterial surfaces and therefore, as DAMPs. Neurons and glial cells, which have been equipped by numerous PRRs, react to Ab and drive immune pathway activation. An increasing expression of inflammatory mediators and the subsequent release of further DAMPs seem able to establish a vicious cycle and sustain brain inflammation, which otherwise, would possibly be terminated. Future studies are required to test whether interference with the involved pathways holds therapeutic promise for patients suffering from neurodegenerative disease. Knowledge on the precise mechanism of action and signaling pathways involved is mandatory before any experimental clinical intervention. AUTHORSHIP C.V. and M.T.H. screened the literature, assembled the figure and wrote the paper jointly.
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